Blog
RSS FeedPosted by Michael Wonder on 14 Jan 2024
1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid
11 January 2024 - A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be ...
Posted by Michael Wonder on 28 Dec 2023
Application for COVID-19 vaccine Nuvaxovid against Omicron variant XBB.1.5 withdrawn
18 December 2023 - The manufacturer Novavax is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland. ...
Posted by Michael Wonder on 21 Dec 2023
Future supply of new COVID-19 vaccines confirmed
20 December 2023 - A vaccine to combat the newer strains of COVID-19 has been approved and will be available ...
Posted by Michael Wonder on 19 Dec 2023
Texas makes a stand against big pharma’s Covid vaccines
19 December 2023 - On the last day of November Texas launched extraordinary legal proceedings that could have wide-ranging political ...
Posted by Michael Wonder on 07 Dec 2023
Evolving our approach to COVID-19 vaccines and treatments
6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...
Posted by Michael Wonder on 05 Dec 2023
EU medicines agencies reflect on lessons learned from COVID-19
1 December 2023 - The European Medicines Regulatory Network has been at the forefront of the fight against COVID-19 with ...
Posted by Michael Wonder on 29 Nov 2023
Japan's Ministry of Health, Labour and Welfare approves CSL and Arcturus Therapeutics' ARCT-154, the first self-amplifying mRNA vaccine approved for COVID in adults
27 November 2023 - Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval. ...
Posted by Michael Wonder on 28 Nov 2023
Daichirona for intramuscular injection for booster vaccination approved in Japan as Omicron XBB.1.5 adapted monovalent mRNA vaccine against COVID-19
28 November 2023 - - Daiichi Sankyo today announced that Daichirona for intramuscular injection (DS-5670) for booster vaccination has been ...
Posted by Michael Wonder on 22 Nov 2023
ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines
20 November 2023 - Recommendations from the Australian Technical Advisory Group on Immunisation on the use of XBB 1.5 COVID-19 vaccines. ...
Posted by Michael Wonder on 20 Nov 2023
New Covid-19 vaccines available to target current variants
20 November 2023 - The Australian Government has accepted the latest advice from the Australian Technical Advisory Group on Immunisation on ...
Posted by Michael Wonder on 31 Oct 2023
EMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.5
31 October 2023 - The EMA’s CHMP has recommended authorising an adapted Nuvaxovid vaccine targeting the Omicron XBB.1.5 subvariant of ...
Posted by Michael Wonder on 30 Oct 2023
COVID-19 treatments to enter the market with a hefty price tag
28 October 2023 - The COVID-19 treatments millions of Americans have taken for free from the Federal Government will enter ...
Posted by Michael Wonder on 22 Oct 2023
End of COVID-19 emergency response
20 October 2023 - A statement from Australia's Chief Medical Officer, Professor Paul Kelly, on the end of the COVID-19 emergency ...
Posted by Michael Wonder on 20 Oct 2023
Pfizer to price Covid drug Paxlovid at $1,390 per course
18 October 2023 - Health insurance plans will likely pay much less than the nearly $1,400 list price for Paxlovid, ...
Posted by Michael Wonder on 16 Oct 2023
EU delays approval of Novavax's revised COVID vaccine
16 October 2023 - European Union regulators have delayed a decision to give approval for Novavax's variant-tailored COVID-19 vaccine, the ...